Venous Technology

BD is committed to staying at the forefront of developing cutting-edge venous technologies to address the unique challenges of the venous anatomy and disease states.

Background Image
tabs dropdown arrow
Overview

Finally, the venous stent you need for the iliofemoral veins.

Developed in collaboration with clinicians, the Venovo™ Venous Stent System is designed with a unique balance of radial strength, compression resistance and flexibility needed for the treatment of both post-thrombotic and non-thrombotic iliofemoral lesions. Additionally, the broad size matrix allows physicians to treat large diameter veins and long lesions.

Proven safe and effective at 24-months1

The VERNACULAR study results provide scientific evidence that the Venovo™ Venous Stent System is safe and effective for the treatment of symptomatic iliofemoral venous outflow obstruction.

  • Primary Patency in Post-Thrombotic Lesions at 24 months1

  • Primary Patency in Non-Thrombotic Lesions at 24 months1

  • Placement Accuracy1

  • Stent Migration1 at 30 days1

  • Stent Fractures at 24 months1

Venovo™ Venous Stent System

Overview and procedure

Designed for Veins

The illiac and femoral veins have unique challenges that must be addressed to reduce venous hypertension due to occlusive disease.

  • Large Caliber

    Veins typically have greater diameters compared to their corresponding arteries.4

  • Diffuse & Focal Lesions

    Long-diffuse lesions tend to be associated with post-thrombotic syndrome (PTS) necessitating longer stent lengths, while non-thrombotic iliac vein lesions (NIVL) tend to be more focal. 5

  • Post-thrombotic changes

    The presence of long fibrotic lesions require venous stents to have high radial force. 4

  • Extrinsic compression

    The presence of external compressions, such as a tumor or May-Thurner Syndrome, require venous stents to have high compression resistance. 4

  • Complex curvature

    Venous stents require high flexibility to accommodate the anatomic course of veins during movement. 4

Purpose-Built Venous Stent

    Placement Accuracy

      Size Offering

      The Venovo™ Venous Stent offers a broad selection of 42 sizing options in both 80 cm and 120 cm catheter lengths to accommodate a variety of iliofemoral lesions.

      Venovo™ Venous Stent in the News
      • PRESS RELEASE - MAR 14, 2019, PR NEWSWIR
        BD Receives U.S. FDA Approval for First Venous Stent to Treat Iliofemoral Venous Occlusive Disease

        Learn More

        forward-arrow
      • NEWS - NOV 9, 2018, VENOUS NEWS
        VERNACULAR trial 12-month data show successful use of Venovo stent in obstructive lesions

        Learn More

        forward-arrow
      • NEWS - SEP 8, 2019, VASCULAR NEWS
        Learn more about the 24-month results of the Venovo Venous Stent VERNACULAR trial

        Learn More

        forward-arrow
      • NEWS - JUNE 13, 2019, VENOUS NEWS
        The new Venovo Venous Stent is changing clinical practice

        Learn More

        forward-arrow
      • NEWS - FEB 28, 2018, VENOUS NEWS

        One-year data from venous stent registry “promising” 3

        Learn More

        forward-arrow
      • NEWS - MAY 4, 2020, VENOUS NEWS
        A Deeper Dive into the Venovo™ Venous Stent System

        Learn More

        forward-arrow

      Discover More

      Be the first to know about venous training opportunities, clinical updates, product launches, conference activities and other venous disease information.

      References
      1. The VENOVO™ Venous Stent System was studied in the global VERNACULAR clinical trial, which was a prospective, multi-center, non-randomized, single-arm study of 170 patients. The primary effectiveness endpoint of the study was primary patency (PP) at 12 months post-index procedure. Patients who received a VENOVO™ Venous Stent had a weighted PP rate of 88.3%, demonstrating a statistically significant difference from a literature-derived performance goal (PG) of 74%. At the 24-month follow-up (N=147), the PP rate was 83.2% with the 95.2% PP in NIVL subgroup and 73.4% PP in the PTS subgroup. The primary safety endpoint was freedom from major adverse events (MAE) through 30 days post-index procedure. Freedom from MAE was 93.5%, demonstrating a statistically significant difference from a literature-derived PG of 89% and 0% stent migration. Secondary endpoints included acute technical success and stent fractures. Results demonstrated 100% acute technical success, defined as successful deployment of stent(s) to intended target with adequate lesion coverage as assessed by the Investigator at the time of the index procedure. Stents were evaluated at the 24-month follow-up for fracture analysis. An anteroposterior and lateral x-ray for each evaluated stent were sent to an independent core lab for analysis. 128 subjects’ x-rays were analyzed and no stent fractures were reported. Missing x-ray analyses were recorded as protocol deviations. VERNACULAR Clinical Study. Data on File. Bard Peripheral Vascular Inc., Tempe, AZ.
      2. Results shown in bench testing. Average foreshortening = 2.9% (values based on mathematical calculations). Data on file, Bard Peripheral Vascular Inc., Tempe, AZ. Bench tests may not be indicative of clinical   performance. Different test methods may yield different results.
      3. Data from the Arnsberg Registry are observational as reported by Dr. Lichtenberg. This is an independent, single-center analysis completed independently without support from BD.
      4. Jalaie H, Schleimer K, Barbati ME, Gombert A, Grommes J et al. (2016) Interventional treatment of postthrombotic syndrome. Gefasschirurgie 21 (Suppl 2): 37-44.
      5. Lichtenberg M, de Graaf R, Erbel C (2018) Standards for recanalisation of chronic venous outflow obstructions. Vasa 47 (4): 259-266.

      The Venovo™ Venous Stent System is indicated for the treatment of symptomatic iliofemoral  venous outflow obstruction.

      The Atlas™ Gold PTA Dilatation Catheter is indicated for use in Percutaneous Transluminal Angioplasty of the peripheral vasculature, including the iliac arteries and iliac and femoral veins, and for the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae. This device is also indicated for post-dilatation of stents and stent franfts in the peripheral vasculature.

      Please consult package insert for all indications, contraindications, hazards, warning, precautions, and information for use. © 2020 BD. BD, the BD logo, Atlas Gold, and Venovo™ are the property of Becton, Dickinson and Company.

      Illustration by Mike Austin. Copyright © 2020.

      Bard Peripheral Vascular, Inc. | www.bardpv.com | 1 800 321 4254 | 1625 W. 3rd Street Tempe, AZ 85281.  BD-12870

      Peripheral IV Catheters
      • Venovo™ Venous Stent System

        Designed to provide the optimal balance between radial force, flexibility, and compression resistance.

        Learn More

        forward-arrow
      • Atlas™ Gold PTA Dilatation Catheters

        Large balloon diameters up to 26mm. Ultra non-compliant technology offers virtually no growth past stated diameter*

        Learn More

        forward-arrow
      References
      1. The VENOVO™ Venous Stent System was studied in the global VERNACULAR clinical trial, which was a prospective, multi-center, non-randomized, single-arm study of 170 patients. The primary effectiveness endpoint of the study was primary patency (PP) at 12 months post-index procedure. Patients who received a VENOVO™ Venous Stent had a weighted PP rate of 88.3%, demonstrating a statistically significant difference from a literature-derived performance goal (PG) of 74%. At the 24-month follow-up (N=147), the PP rate was 83.2% with the 95.2% PP in NIVL subgroup and 73.4% PP in the PTS subgroup. The primary safety endpoint was freedom from major adverse events (MAE) through 30 days post-index procedure. Freedom from MAE was 93.5%, demonstrating a statistically significant difference from a literature-derived PG of 89% and 0% stent migration. Secondary endpoints included acute technical success and stent fractures. Results demonstrated 100% acute technical success, defined as successful deployment of stent(s) to intended target with adequate lesion coverage as assessed by the Investigator at the time of the index procedure. Stents were evaluated at the 24-month follow-up for fracture analysis. An anteroposterior and lateral x-ray for each evaluated stent were sent to an independent core lab for analysis. 128 subjects’ x-rays were analyzed and no stent fractures were reported. Missing x-ray analyses were recorded as protocol deviations. VERNACULAR Clinical Study. Data on File. Bard Peripheral Vascular Inc., Tempe, AZ.
      2. Results shown in bench testing. Average foreshortening = 2.9% (values based on mathematical calculations). Data on file, Bard Peripheral Vascular Inc., Tempe, AZ. Bench tests may not be indicative of clinical   performance. Different test methods may yield different results.
      3. Data from the Arnsberg Registry are observational as reported by Dr. Lichtenberg. This is an independent, single-center analysis completed independently without support from BD.
      4. Jalaie H, Schleimer K, Barbati ME, Gombert A, Grommes J et al. (2016) Interventional treatment of postthrombotic syndrome. Gefasschirurgie 21 (Suppl 2): 37-44.
      5. Lichtenberg M, de Graaf R, Erbel C (2018) Standards for recanalisation of chronic venous outflow obstructions. Vasa 47 (4): 259-266.

      The Venovo™ Venous Stent System is indicated for the treatment of symptomatic iliofemoral  venous outflow obstruction.

      The Atlas™ Gold PTA Dilatation Catheter is indicated for use in Percutaneous Transluminal Angioplasty of the peripheral vasculature, including the iliac arteries and iliac and femoral veins, and for the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae. This device is also indicated for post-dilatation of stents and stent franfts in the peripheral vasculature.

      Please consult package insert for all indications, contraindications, hazards, warning, precautions, and information for use. © 2020 BD. BD, the BD logo, Atlas Gold, and Venovo™ are the property of Becton, Dickinson and Company.

      Illustration by Mike Austin. Copyright © 2020.

      Bard Peripheral Vascular, Inc. | www.bardpv.com | 1 800 321 4254 | 1625 W. 3rd Street Tempe, AZ 85281.  BD-12870

      Literature

      Explaining deep venous disease to patients can be difficult. BD has developed comprehensive patient education materials to help facilitate these conversations. Click the icons to view BD's various venous educational tools. To order these for your practice, access the link below.

      Looking for additional venous education resources dedicated to healthcare professionals? Our venous guide will address common questions regarding diagnosis, treatment options and other technical considerations for venous disease treatment. To learn more, view the deep venous guide below.

      Related Videos
      •  At a Glance: 24-Month VERNACULAR Result

        Dr. Michael Dake, Senior VP for Health Sciences at the University of Arizona and Principal Investigator in the Venovo™ Venous Stent VERNACULAR trial shares key findings from the 24-month clinical results including primary patency rates, target lesion revascularization (TLR) and fracture rates, patient quality of life, and more.

      • Changing Clinical Practice: Venous Experts Discuss the Venovo™ Venous Stent

        Dr. Gerard O'Sullivan, FSIR, FEBIR​ of Galway University Hospitals​ in Galway, Ireland and Dr. Steven Dubenec, MBBS, FRACS, Head of Vascular Surgery at the Royal Prince Alfred Hospital in Sydney, Australia discuss important features of the Venovo™ Venous Stent and their personal experiences using the product. Recorded at the London Charing Cross Symposium in 2019.

      • Post-thrombotic venous stenting in action

        A post-thrombotic case presentation, courtesy of Dr. Rick de Graaf, MD, PhD, Interventional and Neurointerventional...

      • Patient Shares Experience with the Venovo™ Venous Stent

        A patient shares her story three years after receiving a Venovo™ Venous Stent.

      • Venovo™ Venous Stent Case Study by Dr. Dubenec

        Watch the video highlighting Dr. Dubenec’s case with the Venovo™ Venous Stent.

      • Venovo™ Venous Stent NIVL Case Study by Dr. Desai

        Watch the video highlighting Dr. Desai's non-thrombotic iliac vein lesion case with the Venovo™ Venous Stent.

      • Venovo™ Venous Stent PTS Case Study by Dr. Desai

        Watch the video highlighting Dr. Desai's post-thrombotic syndrome case with the Venovo™ Venous Stent.

      • Venovo™ Venous Stent Case Study by Dr. Tiede

        Watch the video highlighting Dr. Tiede's case with the Venovo™ Venous Stent.

      References
      1. The VENOVO™ Venous Stent System was studied in the global VERNACULAR clinical trial, which was a prospective, multi-center, non-randomized, single-arm study of 170 patients. The primary effectiveness endpoint of the study was primary patency (PP) at 12 months post-index procedure. Patients who received a VENOVO™ Venous Stent had a weighted PP rate of 88.3%, demonstrating a statistically significant difference from a literature-derived performance goal (PG) of 74%. At the 24-month follow-up (N=147), the PP rate was 83.2% with the 95.2% PP in NIVL subgroup and 73.4% PP in the PTS subgroup. The primary safety endpoint was freedom from major adverse events (MAE) through 30 days post-index procedure. Freedom from MAE was 93.5%, demonstrating a statistically significant difference from a literature-derived PG of 89% and 0% stent migration. Secondary endpoints included acute technical success and stent fractures. Results demonstrated 100% acute technical success, defined as successful deployment of stent(s) to intended target with adequate lesion coverage as assessed by the Investigator at the time of the index procedure. Stents were evaluated at the 24-month follow-up for fracture analysis. An anteroposterior and lateral x-ray for each evaluated stent were sent to an independent core lab for analysis. 128 subjects’ x-rays were analyzed and no stent fractures were reported. Missing x-ray analyses were recorded as protocol deviations. VERNACULAR Clinical Study. Data on File. Bard Peripheral Vascular Inc., Tempe, AZ.
      2. Results shown in bench testing. Average foreshortening = 2.9% (values based on mathematical calculations). Data on file, Bard Peripheral Vascular Inc., Tempe, AZ. Bench tests may not be indicative of clinical   performance. Different test methods may yield different results.
      3. Data from the Arnsberg Registry are observational as reported by Dr. Lichtenberg. This is an independent, single-center analysis completed independently without support from BD.
      4. Jalaie H, Schleimer K, Barbati ME, Gombert A, Grommes J et al. (2016) Interventional treatment of postthrombotic syndrome. Gefasschirurgie 21 (Suppl 2): 37-44.
      5. Lichtenberg M, de Graaf R, Erbel C (2018) Standards for recanalisation of chronic venous outflow obstructions. Vasa 47 (4): 259-266.

      The Venovo™ Venous Stent System is indicated for the treatment of symptomatic iliofemoral  venous outflow obstruction.

      The Atlas™ Gold PTA Dilatation Catheter is indicated for use in Percutaneous Transluminal Angioplasty of the peripheral vasculature, including the iliac arteries and iliac and femoral veins, and for the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae. This device is also indicated for post-dilatation of stents and stent franfts in the peripheral vasculature.

      Please consult package insert for all indications, contraindications, hazards, warning, precautions, and information for use. © 2020 BD. BD, the BD logo, Atlas Gold, and Venovo™ are the property of Becton, Dickinson and Company.

      Illustration by Mike Austin. Copyright © 2020.

      Bard Peripheral Vascular, Inc. | www.bardpv.com | 1 800 321 4254 | 1625 W. 3rd Street Tempe, AZ 85281.  BD-12870

      Chat with us
      Our live chat is available between the hours of 8.30am - 5.00pm EST, Monday - Friday
      ×